Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 216.83M P/E - EPS this Y 1,850.00% Ern Qtrly Grth -
Income -41.96M Forward P/E 19.28 EPS next Y 66.70% 50D Avg Chg 11.00%
Sales 536.89M PEG - EPS past 5Y -37.00% 200D Avg Chg 32.00%
Dividend N/A Price/Book 1.15 EPS next 5Y - 52W High Chg -62.00%
Recommedations 2.70 Quick Ratio 0.73 Shares Outstanding 65.19M 52W Low Chg 334.00%
Insider Own 11.51% ROA 2.18% Shares Float 35.38M Beta 0.89
Inst Own 65.58% ROE -25.82% Shares Shorted/Prior 1.37M/1.61M Price 3.47
Gross Margin 66.53% Profit Margin -7.82% Avg. Volume 739,746 Target Price 14.50
Oper. Margin 10.12% Earnings Date Nov 5 Volume 184,728 Change -2.80%
About Bioventus Inc.

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

BVS Chatroom

User Image 11thestate Posted - 11 hours ago

$BVS has agreed to a $15.25M settlement with investors to resolve claims related to financial issues, including unexpected refund claims from customers. The filing deadline is in two weeks, December 02, 2024. If you bought between February 11, 2021, and November 21, 2022, you can file for payment here: https://11thestate.com/cases/bioventus-investor-lawsuit

User Image 11thestate Posted - 1 week ago

$BVS has agreed to a $15.25M settlement with investors to resolve claims related to financial issues, including unexpected refund claims from customers. The filing deadline is December 02, 2024. If you bought between February 11, 2021, and November 21, 2022, you can file for payment here: https://11thestate.com/cases/bioventus-investor-lawsuit

User Image 11thestate Posted - 2 weeks ago

$BVS has agreed to a $15.25M settlement with investors to resolve claims related to financial issues, including unexpected refund claims from customers. The filing deadline is December 02, 2024. If you bought between February 11, 2021, and November 21, 2022, you can file for payment here: https://11thestate.com/cases/bioventus-investor-lawsuit

User Image jParkz Posted - 2 weeks ago

News Article $BVS Bioventus Reports Third Quarter Financial Results https://marketwirenews.com/news-releases/bioventus-reports-third-quarter-financial-results-7104535734891163.html $BVS

User Image LewisDaKat Posted - 2 weeks ago

$BVS News Expected US Company Earnings on Tuesday, November 5th, 2024 https://marketwirenews.com/news-releases/expected-us-company-earnings-on-tuesday-november-5th-5642816579866593.html $BVS

User Image VrtcIl Posted - 2 weeks ago

Do not chase $BVS and wait for consolidations to enter with defined risk. Monitoring the chart during consolidation phases can offer more controlled and calculated trades. Price: 11.98 Float: 32.7M Short Float: 4.0 % 💰 Dollar Volume: 3.3K ℹ️ USA | Medical Devices

User Image 50bps Posted - 2 weeks ago

$BVS nice recovery

User Image _www_larval_com_ Posted - 2 weeks ago

$BVS just turned 16% higher to -25% (~239Kv) a few minutes ago, 11/15 options, follow for more volatility.

User Image Charlestrader777 Posted - 2 weeks ago

$BVS good gosh

User Image HaltTradeAlert Posted - 2 weeks ago

$BVS Halt Time: 09:32:35 Issue Symbol: BVS Reason Code: LUDP Last Price: $8.77 Volume: 251.6 K Members get this halt alert with no delay and with more info: shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!

User Image 11thestate Posted - 2 weeks ago

$BVS Deadline Update On Bioventus $15.25M Investor Settlement: https://www.reddit.com/r/pennystocks/comments/1g8vghv/deadline_update_on_bioventus_1525m_investor/

User Image 11thestate Posted - 10/31/24

$BVS has agreed to a $15.25M settlement with investors to resolve claims related to financial issues, including unexpected refund claims from customers. The filing deadline is December 02, 2024. If you bought between February 11, 2021, and November 21, 2022, you can file for payment here: https://11thestate.com/cases/bioventus-investor-lawsuit

User Image 11thestate Posted - 10/24/24

$BVS has agreed to a $15.25M settlement with investors to resolve claims related to financial issues, including unexpected refund claims from customers. The filing deadline is December 02, 2024. If you bought between February 11, 2021, and November 21, 2022, you can file for payment here: https://11thestate.com/cases/bioventus-investor-lawsuit

User Image Skrumpa Posted - 1 month ago

$BVS Long at 12.91 Stop 12.11

User Image 11thestate Posted - 1 month ago

$BVS has agreed to a $15.25M settlement with investors to resolve claims related to financial issues, including unexpected refund claims from customers. The filing deadline is December 02, 2024. If you bought between February 11, 2021, and November 21, 2022, you can file for payment here: https://11thestate.com/cases/bioventus-investor-lawsuit

User Image WeeklyTrader Posted - 1 month ago

Watch for a potential decline! $BVS 12.5p RSI: 66.42% 50-day MA: $10.16 200-day MA: $6.62

User Image BigLineSwings Posted - 1 month ago

$BVS Gogo

User Image 11thestate Posted - 1 month ago

$BVS has agreed to a $15.25M settlement with investors to resolve claims related to financial issues, including unexpected refund claims from customers. The filing deadline is December 02, 2024. If you bought between February 11, 2021, and November 21, 2022, you can file for payment here: https://11thestate.com/cases/bioventus-investor-lawsuit

User Image 30DeltaSpy Posted - 1 month ago

$BVS

User Image 11thestate Posted - 1 month ago

$BVS has agreed to a $15.25M settlement with investors to resolve claims related to financial issues, including unexpected refund claims from customers. The filing deadline is December 02, 2024. If you bought between February 11, 2021, and November 21, 2022, you can file for payment here: https://11thestate.com/cases/bioventus-investor-lawsuit

User Image briefingcom Posted - 1 month ago

$BVS: Bioventus to sell its Advanced Rehabilitation business of its subsidiary Bioness https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241001090728BVS&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image Brianmsc Posted - 09/27/24

$BVS

User Image 11thestate Posted - 09/24/24

$BVS agreed to settle $15.25M with investors to resolve claims related to financial issues. If you bought $BVS between February 11, 2021 and November 21, 2022, you can file for payment here: https://11thestate.com/cases/bioventus-investor-lawsuit

User Image Doozio Posted - 2 months ago

$BVS sure ain’t no dingleberry like CVS during 🧠⏰♾️

User Image ChristaBoarts Posted - 2 months ago

$BVS offers strong growth potential in the healthcare sector with its innovative approach. A stock to watch. Powered by FAAS

User Image Brianmsc Posted - 2 months ago

$BVS Best Value Stock What could go wrong?

User Image Brianmsc Posted - 2 months ago

$BVS Should benefit well from interest rate cuts.

User Image vjtweet Posted - 2 months ago

$BVS on break of the trend line.. high tight flag on a momentum stock.

User Image 11thestate Posted - 2 months ago

$BVS is now accepting claims for a $15.25M settlement it is paying to investors over claims related to financial issues, including unexpected refund claims from customers. The filing deadline is December 02, 2024. If you bought between February 11, 2021 and November 21, 2022, you can file for payment here: https://11thestate.com/cases/bioventus-investor-lawsuit

User Image Stoop_Kid Posted - 08/29/24

$BVS $VBNK $PLMR $LMB smid strength

Analyst Ratings
Craig-Hallum Buy Sep 27, 24
Canaccord Genuity Buy Aug 13, 24
Craig-Hallum Buy Aug 7, 24
Canaccord Genuity Buy May 8, 24
Craig-Hallum Buy Mar 13, 24
Canaccord Genuity Buy Dec 7, 23
Craig-Hallum Hold Apr 3, 23
Goldman Sachs Neutral Nov 30, 22
Craig-Hallum Hold Nov 22, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Bihl Anthony P III Interim CEO Interim CEO Aug 18 Buy 4.14 39,885 165,124 26,595 08/22/23
Bartholdson John A. Director Director Aug 11 Buy 4.69 65,022 304,953 6,833,857 08/15/23
Bartholdson John A. Director Director Aug 10 Buy 4.4741 111,848 500,419 6,768,835 08/14/23
Bartholdson John A. Director Director Jun 12 Buy 2.98 455,725 1,358,060 6,364,861 06/14/23
CHURCH KATRINA J SVP & Chief Complian.. SVP & Chief Compliance Officer Apr 01 Sell 9.27 131 1,214 10,222 06/08/23
Bihl Anthony P III Interim CEO Interim CEO May 23 Buy 2.3279 125,000 290,988 125,000 05/24/23
Bartholdson John A. Director Director May 19 Buy 2.01 1,315,673 2,644,503 5,909,136 05/23/23
Nosenzo John Fmr. Chief Commercia.. Fmr. Chief Commercial Officer Apr 01 Sell 9.27 142 1,316 87,148 04/21/23
CHURCH KATRINA J SVP & Chief Complian.. SVP & Chief Compliance Officer Apr 03 Sell 1.07 117 125 10,353 04/05/23
Singleton Mark Leonard SVP & CFO SVP & CFO Mar 24 Sell 1.27 6,044 7,676 12,581 03/27/23
D'Adamio Anthony SVP & General Counse.. SVP & General Counsel Mar 14 Sell 1.39 3,409 4,739 45,610 03/16/23
Reali Kenneth Michael Chief Executive Offi.. Chief Executive Officer Mar 14 Sell 1.39 9,811 13,637 30,085 03/16/23
CHURCH KATRINA J SVP & Chief Complian.. SVP & Chief Compliance Officer Mar 14 Sell 1.39 1,332 1,851 4,624 03/16/23
Vizirgianakis Stavros G. Director Director Jun 16 Option 0.00 965 2,781,888 06/22/22
Beyer Pat Director Director Jun 16 Option 0.00 965 965 06/22/22
McMurry-Heath Michelle Director Director Jun 16 Option 0.00 385 385 06/22/22
Ladone Mary Kay Director Director Jun 16 Option 0.00 1,813 1,813 06/22/22
D'Adamio Anthony SVP & General Counse.. SVP & General Counsel Apr 01 Sell 11.19 16,016 179,219 40,132 04/05/22
Nosenzo John Chief Commercial Off.. Chief Commercial Officer Apr 01 Sell 11.12 65,963 733,509 83,932 04/05/22
Pavesio Alessandra SVP & Chief Science.. SVP & Chief Science Officer Apr 01 Sell 11.17 32,997 368,576 148,309 04/05/22
Pavesio Alessandra SVP & Chief Science.. SVP & Chief Science Officer Feb 14 Sell 11.99 433 5,192 119,830 02/16/22
D'Adamio Anthony SVP & General Counse.. SVP & General Counsel Feb 11 Sell 11.99 1,294 15,515 18,672 02/15/22
Anglum Gregory O. SVP & CFO SVP & CFO Feb 11 Sell 11.99 1,294 15,515 55,013 02/15/22
Nosenzo John Chief Commercial Off.. Chief Commercial Officer Feb 11 Sell 11.99 534 6,403 43,370 02/15/22